Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

What are the risks of long-term NSAIDs and COX-2 inhibitors? J Fam Pract 2003 Mar;52(3):199-200



Pubmed ID


Scopus ID

2-s2.0-0037335539   1 Citation


This review presents an interesting new analysis of cyclo-oxygenase-2 (COX-2) inhibitor safety, concluding that long-term use results in more serious adverse events than traditional nonsteroidal anti-inflammatory drugs (NSAIDs). The nonsystematic and retrospective properties of this analysis limit its validity. However, the fact that an evaluation of long-term data found some small harm to COX-2 inhibitors relative to traditional NSAIDs (number needed to harm=78 over 9 months) should give clinicians pause. Until better meta-analyses or new safety data are published, clinicians should prescribe COX-2 inhibitors long-term only for those patients deemed to be at high risk of ulcer complications.

Author List

DeBisschop M


Michael Debisschop PharmD Professor in the School of Pharmacy Administration department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Anti-Inflammatory Agents, Non-Steroidal
Arthritis, Rheumatoid
Cyclooxygenase 2
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Evidence-Based Medicine
Membrane Proteins
Practice Guidelines as Topic
Prostaglandin-Endoperoxide Synthases
Retrospective Studies
Risk Factors